Genfit SA may now hold the clearest path to market of the four companies in Phase III for non-alcoholic steatohepatitis (NASH), due largely to the misfortunes of its competitors. Those setbacks, and the progress being made in NASH, were discussed on the sidelines of the American Association for the Study of Liver Diseases annual meeting.
Presumed leader Intercept Pharmaceuticals Inc. has battled safety issues for its candidate Ocaliva (obeticholic acid) due to real-world treatment...